Check patentability & draft patents in minutes with Patsnap Eureka AI!

CD123 binding agent and use thereof

A technology of CDR3 and binding fragments, applied in application, drug combination, peptide, etc., can solve problems such as adverse reactions and obvious side effects

Active Publication Date: 2021-11-26
JANSSEN PHARMA NV
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these therapies can have significant side effects and cause adverse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD123 binding agent and use thereof
  • CD123 binding agent and use thereof
  • CD123 binding agent and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0299] Example 1: Materials

[0300] Generation of CD123 cell line

[0301] Generating a set of people expressed CD123 SP1 ECD (amino acids 20-305 of) (SEQ ID NO: 1), human CD123SP2 ECD (SEQ ID NO: 2 of the amino acids 19-227) and cynomolgus CD123 ECD (SEQ ID NO : the first 3 amino acids 19-305) is pDisplay TM Vector, used as a screening tool for evaluation of anti-CD123-leader. Allowing protein using mammalian expression vectors pDisplay (Invitrogen) (FIG. 1) displayed on the cell surface. By the pDisplay TM Protein expressed at the N-terminus of the murine Ig κ chain leader sequence fused to the sequence of the protein to the secretory pathway and derived growth factor receptor (PDGFR) with the C-terminus of the transmembrane domain of platelet fusion, the protein domain anchored to the plasma membrane, the cell displayed on the outside. By the pDisplay TM Recombinant protein containing the hemagglutinin A and myc epitope, for by Western blot or immunofluorescence assay. CMV p...

Embodiment 2

[0309] Example 2: Identification of anti-human CD123 mAb

[0310] In the four subsequent panning using biotinylated antigen - streptavidin avidin magnetic beads capture method, such as (Rothe et al., J.Mol.Biol.376: 1182-1200,2008; Steidl et al., Mol.Immunol) 46:. in the 135-144,2008), Fab-pIX executor solution panning libraries de novo selected from [Shi, L, et al., J Mol Biol, 2010,397 (2), 385- section. page 396. WO 2009 / 085462], the library with the light chain library Vk1-39,3-11,3-20 and 4-1 and 5-51 VH1-69,3-23 paired heavy chain library components.

[0311] After the fourth round of panning, phagemid DNA from the excised pIX gene, the coding region to generate a soluble Fab HIS tag. Fab expressed in E. coli, and screened with human recombinant CD123 SP1 ECD-HIS tagged protein binding Fab in ELISA. Briefly, PBS solution at 4 ℃ with sheep anti-human Fd (binding site # PC075) at a rate of 1μg / mL coated 96-well Nunc Maxisorp plate (Nunc # 437111), and kept overnight. Fab ex...

Embodiment 3

[0326] Example 3: MSD cells bind to HCD123 SP1, HCD123 SP2 and Cynocd123 SP1

[0327] Using the MSD (Mesoscale) cell binding assays to assess binding pDisplay cells engineered CD123 antibody. The purpose of screening assay is to identify the expression of hCD123 SP1 and SP2 antibody binding to cells and cross-reactivity with cells expressing cynoCD123 SP1.

[0328]The cells were fixed and the phage was measured in triplicate. In short, the CD123 antibody expressing the supernatant or purified expression was 10 μg / mL. 5,000 cells per well were inoculated into a 384-well plate (MA6000, product catalog number L21XB, MSD) and adhered to 2 hours. The cells were then closed for 15 minutes with a PBS solution (GIBCO) of 20% FBS. The antibody supernatant was then added, and it was placed at room temperature for 1 hour. The cells were washed 3 times with PBS, then a jackson imuno study (JACKSON Immuno study) was added at a rate of 1 μg / mL, and incubated at room temperature for 1 hour....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

Provided herein are antibodies that immunospecifically bind to CD123. Also described herein are related polynucleotides capable of encoding said provided CD123-specific antibodies or antigen-binding fragments, cells expressing said provided antibodies or antigen-binding fragments, and associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are also described. For example, the provided antibodies can be used to diagnose, treat, or monitor the progression, regression, or stability of a CD123-expressing cancer; to determine whether a patient should receive cancer treatment; or to determine whether a subject has a CD123-expressing cancer , and thus may be suitable for treatment with CD123-specific anti-cancer therapeutics such as the multispecific antibodies against CD123 and CD3 described herein.

Description

Technical field [0001] The disclosure provided herein relates to a monoclonal antibody, immunopolymerized binding of the immunoposic binding cluster 123 (CD123; also referred to as IL-3Rα), a multispecific antibody of the immunopod-specific binding CD123 and cluster determinants 3 (CD3), and A method of producing and using the antibody. Background technique [0002] A case of new blood cancer patients have been diagnosed every three minutes. The most common blood cancer is leukemia, lymphoma and myeloma. In 2014, 156,420 Americans were diagnosed with these three blood cancer patients. There is a US person died in blood cancer every 10 minutes. Blood cancerology can affect other parts of bone myeloid, blood cells, lymph nodes and lymphatic systems. These blood cancer patients have uneven, especially young people, of which leukemia is the most common cancer type in adolescents in children and ages. [0003] One type of blood cancer cell expression is called CD123 (IL-3Rα) cell mark...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C07K16/30C12N5/20C12N15/13A61K39/395A61P35/00A61P35/02
CPCC07K16/2809C07K16/2866C07K16/3061A61K2039/505C07K2299/00C07K2317/94C07K2317/92C07K2317/622C07K2317/33C07K2317/34C07K2317/55C07K2317/24C07K2317/31C07K2317/21A61P35/00A61P35/02A61P43/00C07K16/2896C07K16/2803C07K2317/565C07K2317/14
Inventor F.高代R.阿塔B.C.哈曼Y.李J.罗R.麦克戴德S.C.波姆兰茨S.H.谭A.特利亚科夫J.惠勒S-J.吴J.F.内梅思
Owner JANSSEN PHARMA NV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com